Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2024
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Dennis J Slamon, Véronique Diéras, Hope S Rugo, et al.
The Oncologist
|
January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
The Oncologist
|
March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Cancer Medicine
|
April 22, 2026
Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study
Debu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.
NPJ Breast Cancer
|
July 1, 2024
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, et al.
JNCI Cancer Spectrum
|
April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
Hope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
The New England Journal of Medicine
|
January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer
Otto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2024
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Dennis J Slamon, Véronique Diéras, Hope S Rugo, et al.
The Oncologist
|
January 31, 2012
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
Isabelle Ray-Coquard, Antoine Italiano, Emmanuelle Bompas, et al.
The Oncologist
|
March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Cancer Medicine
|
April 22, 2026
Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study
Debu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.
NPJ Breast Cancer
|
July 1, 2024
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, et al.
JNCI Cancer Spectrum
|
April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
Hope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
The New England Journal of Medicine
|
January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer
Otto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Page
of 3